2025
SJR Q3
JCR Q4 · 1,3
597 matched articles
SCIE
Journal detail
Journal of Oncology Pharmacy Practice
- Publisher
- SAGE Publications Ltd
- Country
- United Kingdom · Western Europe
- Type
- journal
- ISSN
-
107815521477092X
Integrated evaluation
Scopus side is Scimago SJR; WoS side is Master Journal List + JCR/JIF. Sources are matched on ISSN. WoS / JCR metrics are available for 1997 and later years only.
WoS / JCR data covers 1997 onward.
Scopus
Scopus · Scimago
- SJR 0,426
- Quartile Q3
- H-Index 50
- Cites/doc 1,36
- Docs (3y) 809
- Cites (3y) 1.093
Clarivate
Web of Science · JCR · 2025
- JCR Q Q4
- JIF 1,3
- 5Y JIF 1,3
- JCI 0,23
WoS indexes
- SCIE
Subject classification
Categories (SJR)
Areas
WoS categories
Yearly quartile comparison
Scimago (SJR) for all years; Clarivate (JCR / JIF / JCI) from 1997 onward. Latest year stays open; older years start collapsed.
WoS / JCR data covers 1997 onward.
| Year | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q3 | Q4 | 0,426 | 1,3 | 1,3 | 0,23 | Q4 | 50 |
| 2024 | Q3 | Q4 | 0,424 | 0,9 | 1,2 | 0,23 | Q4 | 47 |
| 2023 | Q3 | Q4 | 0,408 | 1 | 1,2 | 0,26 | Q4 | 47 |
| 2022 | Q3 | Q4 | 0,467 | 1,3 | 1,4 | 0,29 | Q4 | 47 |
| 2021 | Q3 | Q4 | 0,374 | 1,4 | 1,5 | 0,31 | Q4 | 47 |
| 2020 | Q3 | Q4 | 0,548 | 1,8 | 1,9 | 0,46 | Q3 | 47 |
| 2019 | Q3 | Q4 | 0,442 | 1,9 | 1,7 | 0,47 | Q3 | 47 |
| 2018 | — | Q3 | — | 1,8 | — | 0,46 | Q3 | — |
| 2017 | Q2 | Q3 | 0,59 | 1,9 | — | 0,48 | Q3 | 47 |
| 2016 | Q2 | Q3 | 0,546 | 1,7 | — | — | — | 47 |
| 2015 | Q3 | — | 0,424 | — | — | — | — | 47 |
| 2014 | Q2 | — | 0,418 | — | — | — | — | 47 |
| 2013 | Q3 | — | 0,384 | — | — | — | — | 47 |
| 2012 | Q2 | — | 0,39 | — | — | — | — | 47 |
| 2011 | Q2 | — | 0,37 | — | — | — | — | 47 |
| 2010 | Q3 | — | 0,245 | — | — | — | — | 47 |
JCR category quartile history
JCR / JCI quartile by year and category. 1997 and later.
WoS / JCR data covers 1997 onward.
| Year | Category | Edition | JCR Q (1997+) | JCI Q (1997+) | Rank |
|---|---|---|---|---|---|
| 2025 | ONCOLOGY | SCIE | Q4 | Q4 | 292/333 |
| 2025 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q4 | 299/356 |
| 2024 | ONCOLOGY | SCIE | Q4 | Q4 | 290/328 |
| 2024 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q4 | 312/352 |
| 2023 | ONCOLOGY | SCIE | Q4 | Q4 | 287/322 |
| 2023 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q4 | 301/354 |
| 2022 | ONCOLOGY | SCIE | Q4 | Q4 | 226/241 |
| 2022 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q4 | 252/278 |
| 2021 | ONCOLOGY | SCIE | Q4 | Q4 | 232/245 |
| 2021 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q4 | 254/279 |
| 2020 | ONCOLOGY | SCIE | Q4 | Q3 | 225/242 |
| 2020 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q3 | 231/276 |
| 2019 | ONCOLOGY | SCIE | Q4 | Q3 | 213/244 |
| 2019 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q3 | 206/271 |
| 2018 | ONCOLOGY | SCIE | Q4 | Q3 | 193/230 |
| 2018 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 194/267 |
| 2017 | ONCOLOGY | SCIE | Q4 | Q3 | 181/223 |
| 2017 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 183/261 |
| 2016 | ONCOLOGY | SCIE | Q4 | — | 171/217 |
| 2016 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 184/257 |